Objective-Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. Activity of the local kallikrein-kinin system may be important in cardiovascular disease. The effect of kinin B2 receptor (B2R) agonist and antagonist peptides on experimental AAA was investigated. Approach and Results-AAA was induced in apolipoprotein E-deficient mice via infusion of angiotensin II (1.0 μg/kg per minute SC). B2R agonists or antagonists were given via injection (2 mg/kg IP) every other day. The B2R agonist (B9772) promoted aortic rupture in response to angiotensin II associated with an increase in neutrophil infiltration of the aorta in comparison to controls. Mice receiving a B2R/kinin B1 receptor antagonist (B9430) were relatively protected from aortic rupture. Neutrophil depletion abrogated the ability of the B2R agonist to promote aortic rupture. Progression of angiotensin II-induced aortic dilatation was inhibited in mice receiving a B2R antagonist (B9330). Secretion of metalloproteinase-2 and -9, osteoprotegerin, and osteopontin by human AAA explant was reduced in the presence of the B2R antagonist (B9330). B2R agonist and antagonist peptides enhanced and inhibited, respectively, angiotensin II-induced neutrophil activation and aortic smooth muscle cell inflammatory phenotype. The B2R antagonist (B9330; 5 μg) delivered directly to the aortic wall 1 week post-AAA induction with calcium phosphate in a rat model reduced aneurysm growth associated with downregulation of aortic metalloproteinase-9. Conclusions-B2R signaling promotes aortic rupture within a mouse model associated with the ability to stimulate inflammatory phenotypes of neutrophils and vascular smooth muscle cells. B2R antagonism could be a potential therapy for AAA. (Arterioscler Thromb Vasc Biol. 2016;36:898-907.
A bdominal aortic aneurysm (AAA) is the degenerative weakening and dilatation of the abdominal aorta affecting 2% to 5% of men aged >65 years. The natural history of most small AAAs is expansion to a size where surgical repair is indicated. The main complication of AAA is aortic rupture which is associated with a mortality of ≈80%. 1 There is great current interest in identifying targets for the development of drug therapies that can effectively limit AAA growth and aortic rupture. 2, 3 Chronic aortic inflammation is thought to play a significant role in AAA pathogenesis through multiple mechanisms, including the release of proteolytic enzymes, such as matrix metalloproteinases (MMPs) from infiltrating leukocytes, and the generation of reactive oxygen species that induce an inflammatory phenotype in vascular smooth muscle cell (VSMC). 4 Kinins (bradykinin, kallidin) are potent vasodilator peptides released by the proteolytic cleavage of kininogen by kallikrein. 5 The physiological functions of bradykinin are mediated via the constitutively expressed B2 receptor (B2R). 5 The B2R system is a physiological antagonist of the angiotensin II (AngII) type 1 receptor (AT 1 R) system, 6 and deficiency in B2R receptor function is associated with hypertension, left ventricular hypertrophy, and cardiomyopathy. 7 Kinin B1 receptors (B1R) are expressed during inflammatory conditions. 5, 8 Activation of the B1R on neutrophils induces chemotaxis and triggers the release of MMP-9 and myeloperoxidase, 9 whereas the B2R is involved in the extravascular migration of these cells at sites of inflammation. 10, 11 Macrophages express both B2R and B1R, and their stimulation results in the generation of proinflammatory mediators. 12, 13 B2R activation stimulates inflammatory pathways in VSMC. 14 Deficiency of kininogen 15 and the B1R 16 has been reported to promote aortic aneurysm in different rodent models.
Although these observations suggest the potential importance of kinin receptor signaling in aortic aneurysm pathogenesis, there has been limited direct study of this. We used B2R agonist and antagonist peptides within rodent models of aortic aneurysm, human AAA explant, and cell culture studies to investigate the effects and potential cellular mechanisms of B2R signaling in the pathogenesis of aortic aneurysm.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Angiotensin II-Induced Aortic Aneurysm and Rupture Is Reduced by a B2R/B1R Antagonist But Increased by a B2R Agonist
The effect of kinin receptor activation and blockade on AngII-induced aortic dilatation was investigated in apolipoprotein E-deficient (ApoE −/− ) mice. Mice were administered either control (saline), the B2R/B1R antagonist B9430, or the B2R agonist B9972 at 2 mg/kg via 100 μL injection IP every other day during an AngII infusion period of ≤28 days. Infusion of AngII was associated with aortic rupture in 9 of 27 (33%) control mice ( Figure 1A and 1B). The response to AngII was considerably less in mice administered the B2R/ B1R antagonist with aortic rupture in only 2 of 24 mice (8%; P=0.043; Fisher exact test; Figure 1A and 1B). In contrast, the response to AngII was more severe in mice administered a B2R agonist with aortic rupture occurring in 17 of 25 (68%) mice, twice that of control (P=0.025; Fisher exact test; Figure 1A and 1B). Aortic rupture was either acute (day 4-11) or late (day 18-22; Figure 1A ). Aortic rupture after B2R agonist administration was predominantly acute (day 4-7). Aortas from mice were harvested after euthanasia at day 28 or after aortic rupture where possible ( Figure I in the online-only Data Supplement). The rupture sites were restricted to either the aortic arch or the suprarenal aorta (SRA). In the B2R agonist group, there were 8 mice with arch ruptures only, 4 mice with SRA rupture only, and 5 mice with rupture of both the arch and SRA. The 2 aortic ruptures in B2R/B1R antagonist group occurred within the SRA only ( Figure I in the online-only Data Supplement). We measured the maximum diameter of the aortic arch, thoracic aorta, SRA, and infrarenal aorta in all mice surviving the 28-day AngII infusion period (ie, excluding mice with ruptured aortas). Median maximum diameters of the aortic arch and SRA were significantly smaller in mice receiving the B2R/ B1R receptor antagonist compared with control ( Table 1) . The effect of the B2R agonist and B2R/B1R antagonist on B2R gene expression within the SRA was determined at the end of the study (day 28) in surviving mice. Aortic Bdkrb2 was downregulated 3-fold in mice receiving the B2R agonist compared with control ( Figure II 
A B2R Agonist Promotes an Acute Aortic Inflammatory Response Associated With Aortic Rupture
Aortic rupture was exacerbated by a B2R agonist, whereas B2R/B1R antagonism protected against AngII-induced rupture. Examination of histological sections from the site of acute aortic rupture showed that the event was associated with complete break of the elastic lamina and formation of a pseudo-lumen and characterized by the intramural presence of monocyte/macrophages and neutrophils ( Figure III in the online-only Data Supplement). In a separate experiment, we examined whole aortas of AngII-infused mice receiving a B2R agonist, a B2R/B1R antagonist, or control for 8 days using flow cytometry to determine which inflammatory cell types were mainly present within the aortic wall. A significantly greater number of neutrophils were observed within aortas of mice administered the B2R agonist, with a median (interquartile range) percentage difference in mean cell number relative to the control of 328% (209%-347%; P=0.008, n=5; Figure 2 ). A similar, but nonsignificant, median percent difference in the number of macrophages, relative to control, of 142% (128%-367%) was found. The percentage of aortic neutrophils and macrophages were reduced but not significantly different from controls in mice administered the B2R/ B1R antagonist (67%, 49%-85% and 84%, 41%-105%, respectively; Figure 2 ).
A B2R Agonist Augments AngII-Stimulated Activation of Neutrophils In Vitro
We postulated that modulation of B2R signaling within neutrophils may be an important cellular mechanism for the observed in vivo effects of B2R activation and blockade. The action of the B2R agonist B9972 and the B2R antagonist B9330 on AngII-stimulated neutrophil activation was investigated in vitro. Culture supernatants were assayed for activity of myeloperoxidase, a hallmark indicator of the neutrophil respiratory burst, as a measure of neutrophil activation. Myeloperoxidase activity was 6-fold above controls within supernatants of neutrophils exposed to AngII ( Figure 3A ). Addition of a B2R agonist to AngII-stimulated neutrophils significantly increased myeloperoxidase activity within the supernatant of these cells which were 1.7-fold higher compared with cells exposed to AngII alone ( Figure 3A ). Incubation of AngII-stimulated neutrophils with a B2R antagonist, however, suppressed myeloperoxidase activity within the supernatant from these cells which were 3-fold lower than in cells exposed to AngII alone ( Figure 3A ).
Neutrophil Deficiency Limits AngII-Induced Aortic Dilatation in the Presence of a B2R Agonist
Our in vitro findings suggested that increased neutrophil activation via the B2R may be a mechanism important in aortic aneurysm. We thus assessed whether the adverse effect of the B2R agonist to promote aortic rupture in vivo was neutrophil-dependent. The effect of systemic neutrophil deficiency on the ability of the B2R agonist B9972 to exacerbate AngII-induced aortic aneurysm in the mouse model Data expressed as median (interquartile range) maximum diameter (mm). AngII indicates angiotensin II; B9972, B2R agonist; B9330, B2R antagonist; IRA, infrarenal aorta; n, number of mice per group; P1, P value for B9972 vs control by Kruskal-Wallis test with Dunn's post hoc correction; P2, P value for B9330 vs control by Kruskal-Wallis test with Dunn's post hoc correction; SRA, suprarenal aorta; and TA, thoracic aorta.
Figure 2.
Acute inflammatory cell infiltration within the aorta by a B2R agonist preceding vessel rupture. Number of macrophages (gray) and neutrophils (white) within whole aortas of angiotensin II (AngII)-infused mice receiving a B2R agonist (B9972; n=5) or a B2R/B1R antagonist (B9430; n=4) determined by flow cytometry after 8 days of AngII infusion. Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for mean cell number relative to control (dotted line, 100%); *P=0.008. B1R indicates kinin B1 receptor; and B2R, kinin B2 receptor.
was examined in a separate experiment. Administration of a polymorphonuclear neutrophil antibody depleted circulating CD11b + Ly6G + cells (neutrophils) by ≈50% after a 6-day administration period ( Figure 3B ). Seven of the 12 mice (58%) receiving the B2R agonist plus isotype IgG died prematurely because of aortic rupture during a 14-day AngII infusion period, similar to the effect of the agonist in our initial mouse study. In contrast, only 2 of 12 mice (17%) that were neutrophil-deficient which received the B2R agonist during the 14-day AngII-infusion period died because of aortic rupture (P<0.05). Morphometric analysis of aortas demonstrated a significant reduction in median maximum SRA diameter in mice administered anti-polymorphonuclear neutrophil antibody compared with that of the IgG control (P=0.015; Figure 3C ; Figure IV in the online-only Data Supplement). Plasma myeloperoxidase concentration was determined in 8 control mice and 10 neutrophil-deficient mice remaining at day 7 and calculated as percentage-change relative to the concentration measured at baseline (day 0). Mice receiving isotype control IgG exhibited a median increase in plasma myeloperoxidase of 23% (10%-34%; Figure 3D ). Conversely, mice receiving polymorphonuclear neutrophil antibody had a 31% (20%-38%) reduction in median plasma myeloperoxidase relative to baseline (P=0.005; Figure 3D ).
A B2R Antagonist Inhibits Progression of AngII-Induced Aortic Dilatation
The findings detailed above demonstrate that a B2R agonist promotes while a B2R/B1R antagonist limits AngII-induced aortic dilatation and rupture in the mouse model. In clinical practice, a therapy is needed to limit the growth of established aortic aneurysms. We therefore examined whether the B2R antagonist B9330 would limit progression of established AngII-induced AAA. Twenty-four mice having been infused with AngII for 28 days were allocated to receive either the B2R antagonist (n=12; 2 mg/kg every other day via IP injection) or control (n=12) for an additional 28 days, stratified by ultrasound-measured SRA diameter, such that the median and interquartile range of SRA diameter were similarly matched between the 2 groups ( Figure 4A ). All 24 mice survived to the end of the experimental period. Diameter of the SRA was monitored with ultrasound. Maximum SRA diameter at the end of the study (day 56) in control mice was ≈1.5-fold greater than at day 28 (P<0.05; Figure 4B ). In contrast, mice administered the B2R antagonist exhibited no significant change in maximum SRA diameter over the same 28-day period ( Figure 4B ). The effect of the antagonist in limiting SRA growth was confirmed on harvest of aortas at the end of the study ( Figure V in the online-only Data Supplement). Morphometric analysis of aortas revealed significantly smaller maximum diameter of the aortic arch, thoracic, and suprarenal regions in mice receiving the B2R antagonist ( Figure 4C ) and an overall reduced mean maximum aortic diameter compared with control (1.34±0.05 mm and 1.68±0.09 mm, respectively; P=0.01).
Reduced MMP2, MMP9, Osteopontin, and Osteoprotegerin Secretion in Human AAA Explant Exposed to a B2R Antagonist
Upregulation of MMP2, MMP9, osteoprotegerin, and osteopontin has been demonstrated in the aorta of AngII-infused ApoE −/− mice and human AAA tissue. [17] [18] [19] [20] B2R agonist bradykinin upregulates MMP2 and MMP9 expression. 21, 22 We evaluated kinin receptor expression and the effect of the B2R antagonist on the above mentioned markers in biopsies taken from aortas of patients undergoing open AAA repair to assess the clinical relevance of our mouse model and in vitro findings. Immunostaining demonstrated the presence of both B2R and B1R subtypes throughout the aneurysmal wall colocalized with resident vascular cells and inflammatory infiltrate ( Figure VI in the online-only Data Supplement). Gene expression and protein for each subtype was assessed in tissue from the maximally dilated aneurysm body compared with the relatively nondilated aneurysm neck. mRNA for both receptors was increased, relative to GAPDH, in AAA body compared with AAA neck; however, the increase in median mRNA and protein levels were significant for the B2R only ( Figure VII and VIII in the online-only Data Supplement). In line with this, the median ratio of B2R-to-B1R expression was significantly higher in AAA body compared with AAA neck ( Figure 5 ). AAA tissue maintained in culture was exposed to the B2R antagonist B9330 for 3 days, after which supernatant levels of MMP2, MMP9, osteopontin, and osteoprotegerin were determined. Median levels of MMP9 were markedly lower in conditioned media from tissue incubated in the presence of the B2R antagonist compared with supernatants from untreated explant ( Figure IX and Table I in the online-only Data Supplement). Similarly, supernatant . Administration of a B2R antagonist slows the progression of angiotensin II (AngII)-induced aortic dilatation in the ApoE −/− mouse. A, Stratification of mice to control (n=12) or intervention (B9330; n=12) groups based on similarly matched median and interquartile range of suprarenal aorta (SRA) diameter, determined by ultrasound following an aneurysm establishment period with AngII infusion for 28 days. B, Ultrasound measurement of SRA dilatation over 28 days in ApoE −/− mice receiving a B2R antagonist (B9330; white) or control (gray) after an initial 28-day AngII infusion period. Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for maximum diameter (mm); P value calculated for difference between groups by mixed-effects linear regression. C, Regional aortic diameter for AngII-infused ApoE −/− mice administered a B2R antagonist (B9330; white; n=12) or control (gray; n=12) determined by morphometry at euthanasia (Continued) osteopontin and osteoprotegerin were significantly lower for explants incubated in the presence of the B2R antagonist than for control explants ( Table I in 
B2R Agonist and Antagonist Peptides Modulate Aortic VSMC Phenotype in AngII-Infused ApoE −/− Mice and AngII-Stimulated Human Aortic Smooth Muscle Cell In Vitro
There is evidence that phenotype switching in aortic smooth muscle cell (AoSMC) contributes to structural degeneration of the aortic media. 23, 24 We assessed gene expression in the SRA for the SMC differentiation marker calponin 1 (CNN1) and associated mitogen-activated protein kinase 1/3 (MAPK1/3) in a subset of AngII-infused mice administered either the B2R agonist or B2R antagonist. mRNA expression for CNN1 and MAPK1/3 (relative to Gapdh) was downregulated 4-and 2-fold, respectively, in mice receiving the B2R agonist compared with control mice (Table 2 ). In contrast, mRNA for CNN1 was increased 3-fold in mice administered the B2R antagonist, with no significant change in Mapk1/3 expression ( Table 2) . We examined the response of AngIIstimulated human AoSMC in vitro to the B2R agonist B9972 and the B2R antagonist B9330 in terms of mRNA expression for genes associated with AoSMC function. Exposure of AoSMC to AngII (10 μM) over 24 hours promoted an inflammatory phenotype associated with downregulation in mRNA for CNN1 and B-cell lymphoma 2 (BCL2) and increased expression of transcripts for nuclear factor κ-light chain enhancer of activated B cells (NFκB1), MMP9, and Bcl2-like protein 4 (BAX; Table II in the online-only Data Supplement). Co-incubation of AngII-activated AoSMC with the B2R agonist (10 μM) over 24 hours resulted in a 2-fold increase in mRNA for mitogen-activated protein kinase 14 (MAPK14) and MMP2 (Table 2 ). Co-incubation of these cells with the B2R antagonist (10 μM) resulted in downregulation in NFkB1 and MMP9 expression by 3-and 5-fold, respectively, compared with cells incubated with AngII alone (Table 2) . Moreover, 2-, 4-, and 6-fold increases in the negative regulator of MAPK14, dual specificity protein phosphatase 1, MAPK1/3, and CNN1expression, respectively, were observed in AngII-activated AoSMC incubated with the B2R antagonist compared with AngII alone ( Table 2 ).
Site-Directed Delivery of a B2R Antagonist at the Aortic Wall Inhibits CaPO 4 -Induced Dilatation
Protection against aortic dilatation and rupture in response to AngII was demonstrated in our mouse model with systemic administration of a B2R antagonist. We assessed the feasibility and efficacy of administrating a B2R antagonist directly to the aortic wall to limit CaPO 4 -induced AAA in a rat model. Perivascular application of CaPO 4 to the infrarenal aorta resulted in a median maximum infrarenal aortic diameter of 2.02 mm (1.89-2.13 mm) after 28 days compared with 1.50 mm (1.30-1.55 mm) in sham controls (P<0.01; Figure X in the online-only Data Supplement). Microinfusion of a single dose of the B2R antagonist B9330 (5 μg) at the aneurysm site 1 week post CaPO 4 application significantly reduced median maximum infrarenal aortic diameter after the 4-week induction period compared with controls (P=0.002; Table 3 ; Figure  X and XI in the online-only Data Supplement). A significant reduction in mRNA expression and protein for MMP-9 within the infrarenal aorta was associated with smaller diameters observed in mice administered the B2R antagonist at the aneurysm site (Table 3 ).
Discussion
We report the effect of kinin agonist and antagonist peptides on experimental aortic aneurysm. In vivo and in vitro data are presented to support a contributing role for B2R signaling in aortic wall weakening.
Medical treatment for aortic aneurysm aims to limit the main complication of aneurysm rupture. Aneurysm diameter is an important clinical indicator of rupture risk for AAA Figure 5 . Expression ratio favors B2R within human abdominal aortic aneurysm (AAA) tissue. A, Ratio of B2R mRNA (BDKRB2) to B1R mRNA (BDKRB1) expression, relative to GAPDH, within human AAA tissue from the maximally dilated aneurysm body (n=6) compared with tissue from the relatively nondilated aneurysm neck (n=6) determined by quantitative polymerase chain reaction (qPCR). Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for mRNA expression ratio; *P=0.002 by Mann-Whitney U test. B, Ratio of B2R to B1R protein within human AAA tissue from the maximally dilated aneurysm body (n=7) compared with tissue from the relatively nondilated aneurysm neck (n=7) determined by Western blotting. Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for protein expression ratio; *P=0.026 by Mann-Whitney U test. B1R, kinin B1 receptor; B2R, kinin B2 receptor. and is routinely used in the selection of patients for surgical intervention. 25 We used the AngII-infused ApoE −/− mouse model of aortic aneurysm in which arterial inflammation and breaks in medial elastic lamellae lead to acute aortic rupture in ≈30% of mice. 26 This model allowed the assessment of both survival free from aortic rupture and maximum aortic diameter. The main findings of this study were that administration of a B2R agonist enhanced the response to AngII and increased aortic rupture in our mouse model, whereas a B2R antagonist reduced aortic dilatation and rupture.
The findings of our study align with a known role for kinins to activate innate and adaptive immune mechanisms via the B2R. 10, 11, 13, 27 Expression of the B2R in neutrophils is involved in the extravascular migration of these cells at sites of inflammation. 10, 11 The significant increase in neutrophil presence observed within the aorta of mice receiving a B2R agonist and reduced numbers of these cells within aortas of mice receiving a B2R antagonist emphasizes the importance of the B2R in promoting neutrophil accumulation within the aorta. Neutrophils are unique among leukocytes in that they contain the complete system for the synthesis and release of bioactive kinins. 28 Moreover, serine proteinases produced by activated neutrophils catalyze kinin formation, resulting in an additional pathway for increased kinin activity and further leukocyte activation. 29 Neutropenia has been shown to reduce experimental AAA. 30 Protection of AngII-infused mice against the detrimental effect of a B2R agonist was afforded by neutrophil depletion in the current study. In vitro, the B2R agonist promoted release of myeloperoxidase from AngIIstimulated neutrophils. Together, these findings suggested that the increased severity of aortic rupture observed in mice receiving the B2R agonist peptide was at least in part mediated by neutrophils.
Previous studies suggest that a phenotype switch in AoSMC favors weakening of the aortic wall and is an important mechanism in AAA pathogenesis. 23, 24 De-differentiation of VSMC to an inflammatory phenotype in response to Table 2 vascular injury involves modulation of genes involved in the regulation of smooth muscle contraction. 31 Phenotypic modulation is associated with reduction in MAPK1/3 activation, resulting in loss of contractile properties. 32 CNN1 facilitates signal transduction by MAPK1/3, 33 and Cnn1 deletion in differentiated VSMCs results in impaired MAPK1/3 activity and cell contractility. 34 Evidence also suggests that MAPK1/3 possesses actin-binding properties and that an intact actin cytoskeleton, degraded during apoptosis, is required for MAPK1/3 signaling. 35 The marked downregulation in CNN1 and MAPK1/3 gene expression within the SRA of mice administered the B2R agonist and the upregulation of mRNA for CNN1 in mice receiving a B2R antagonist suggests that the promotion and inhibition of aortic rupture by the B2R agonist and B2R antagonist, respectively, may involve AoSMC phenotype changes.
. Effect of B2R Agonist and B2R Antagonist Peptides on the Expression of Selected Genes in the Aorta of AngII-Infused ApoE −/− Mice and AngII-Stimulated Human AoSMC In Vitro
Incubation of human AAA explants with a B2R antagonist significantly reduced the production of proinflammatory markers associated with AAA growth. [17] [18] [19] [20] This, with our mouse model data, suggested that signaling via the B2R is likely to be involved in pro-aneurysmal effects of kinins. Kinin can be generated by VSMC locally within the artery wall, resulting in autocrine activation of these cells via the B2R. 36 AT 1 R and B2R are coexpressed in VSMC, 37 and interaction between B2R and AT 1 R has been purported to increase activation of G-protein signaling triggered by AT 1 R. 38 The B2R gene (BdkrB2) is itself a downstream target of the AT 1 R signaling pathway 39 and AngII-mediated upregulation of B2R in VSMC has been demonstrated in vitro and in mouse models. 40, 41 We examined the effect of agonist and antagonist B2R peptides on AngII-activated human AoSMC in vitro and demonstrated that B2R activation augmented an AngII-induced inflammatory phenotype in these cells (eg, upregulation of MAPK14 and MMP2). The contrasting effect of the B2R antagonist (eg, downregulation of NFκB1 and MMP9 and upregulation of CNN1, MAPK1/3, and dual specificity protein phosphatase 1) indicated that modulation of B2R signaling affects markedly the response of AoSMC to AngII.
Gene expression for B2R within the SRA was downregulated significantly in mice administered the B2R agonist compared with controls; however, because analysis was performed on SRA samples harvested at study end, this may reflect desensitization in response to the B2R agonist. Both B1R and B2R were present within biopsies of human AAA, although the expression profile within tissue from the maximally dilated aneurysm body favored the B2R. We found that systemic administration of a B2R antagonist inhibited aortic dilatation within the AngII mouse model. However, although short-term treatment with a B2R antagonist is in clinical use, 42 the feasibility and safety of systemically administrating B2R antagonists over a prolonged period is not known. The positive effect of intra-articular administration of a B2R antagonist reported in osteoarthritis patients 43 is an example of the potential for site-directed intervention. We found that a single-dose delivery of a B2R antagonist to the aortic wall post induction of AAA in a second rodent model was effective and sufficient to reduce MMP9 within the aortic wall and limited aortic expansion. The use of delivery systems to administer a B2R antagonist in a controlled manner directly and discretely at the site of the AAA could potentially offer a more effective alternative to systemic medication with increased benefit to the patient. This approach does, however, remain to be established as a means to safely administer interventions in patients.
Limitations of the study are acknowledged. First, the antagonist peptide B9430 used in the initial mouse study has affinity for both B1 and B2 receptor subtypes, and it is acknowledged that antagonism of B1R may have contributed to the protective effect of B9430 seen in this study. Functional expression of both B2 and B1 receptor subtypes is constitutive in the mouse abdominal aorta. 44 Our assumption that the effect resulted primarily from B2R blockade was based on the marked opposing effect of B2R activation in our study and previous data reporting that B1 deficiency promoted aortic aneurysm. 16 Moreover, initial characterization studies demonstrated that receptor binding and functional activity for B9430 was more potent at the B2 receptor subtype. 45 The specific B2R antagonist B9330 was used in subsequent animal and in vitro studies. Second, the effect of systemically administered B2R agonist and antagonist peptides on aneurysm formation was investigated using the AngII-ApoE −/− mouse model only. This model was used because it simulates both aortic expansion and rupture seen in human AAA. The study was supplemented, however, by an investigation using sitedirected delivery of a B2R antagonist in rats in which AAA was induced using perivascular application of CaPO 4 with similar findings.
In summary, the current study suggests a role for B2R signaling in promoting aortic aneurysm growth and rupture. In vitro, B2R agonist and antagonist peptides enhanced and inhibited, respectively, AngII-induced neutrophil activation and inflammatory phenotype in AoSMCs. Production of proinflammatory proteins associated with AAA growth (MMP9, osteoprotegerin, and osteopontin) was reduced in human AAA explant cultured in the presence of a B2R antagonist. Administration of a B2R agonist within a mouse model amplified the response to AngII and increased aortic rupture, whereas a B2R antagonist limited aneurysm expansion and reduced aortic rupture. Our findings suggest that B2R antagonism could be a treatment target to limit AAA development and progression. 
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